The pharmaceutical sector moved, and many individual stocks such as Zhongsheng Pharmaceutical and Lingkang Pharmaceutical rose and stopped

【Pharmaceutical Network Pharmaceutical Stock Market】News on November 4, the pharmaceutical sector changed, Zhongsheng Pharmaceutical, Lingkang Pharmaceutical, Kangchen Pharmaceutical, Tuspark Pharmaceutical and many other stocks rose and stopped, and CanSino, Junshi Biologics, Hanyu Pharmaceutical and other stocks followed suit
.
Zhongsheng Pharmaceutical: 20 ups and downs in the past year As of 11:00 on November 4, Zhongsheng Pharmaceutical raised the sealing board to 24.
64 yuan, with a turnover of 1.
095 billion, a turnover rate of 6.
57%, and a price-to-earnings (TTM) of 94.
39
.
The stock has risen and stopped 20 times in
the past year.
The main business of Zhongsheng Pharmaceutical is drug research and development, production and sales
.
The company's main products are compound thrombotic series products, Zhongsheng pill series products, cefixime dispersible tablets, cephradine capsules, sucralfate oral suspension
.
Based on a deep understanding of respiratory diseases, especially the development of antiviral drugs, its holding subsidiary, Zhongsheng Ruichuang, systematically carries out scientific research and evaluation in accordance with scientific methods, and actively promotes the process of new drug research and development, and the antiviral project of Zhongsheng Ruichuang is still in the preclinical stage
.
Lingkang Pharmaceutical: 3 ups and downs in the past year As of 11:00 on November 4, Lingkang Pharmaceutical touched the price limit, quoting 6.
02 yuan, with a turnover of 58.
61 million, a turnover rate of 1.
39%, and a price-earnings (TTM) loss
.
The stock has risen and stopped 3 times in
the past year.
The company is mainly engaged in the research and development, production and sales of chemical prescription drugs, and the main products are cardiovascular and cerebrovascular products (Huperzine A for injection, niergoline for injection, etc.
).

On the news, Lingkang Pharmaceutical issued an announcement on the evening of November 3, saying that the company repurchased shares for the first time on March 29, 2022, and as of October 31, 2022, the company has repurchased about 3.
88 million shares through centralized bidding transactions, accounting for 0.
5379% of the company's total share capital, and the total amount paid is about 28.
77 million yuan
.
Kangchen Pharmaceutical: 4 ups and downs in the past year As of 11:00 on November 4, Kangchen Pharmaceutical is also in a state of up and down, the stock is quoted at 28.
74 yuan, the turnover is 146 million, the turnover rate is 3.
28%, and the price-earnings (TTM) is 40.
18
.
The stock has risen and stopped 4 times in
the past year.
According to the data, Kangchen Pharmaceutical is an innovative drug enterprise
that adheres to the research and development of innovative drugs as the core and clinical needs as the guide, integrating research and development, production and sales.
At present, the company's products and products under research mainly focus on hematology, orthopedics and oncology and other areas
with large market space.
TusPharmaceutical: 8 ups and downs in the past year TusPharma was up and down intraday on November 4, 6.
15%, as of 11:00 on the 4th, the stock was quoted at 12.
42 yuan, with a turnover of 485 million, a turnover rate of 16.
34%, and a price-earnings (TTM) of 246.
38
.
The stock has risen and stopped 8 times in
the past year.
As for the reasons for the change in the stock, the analysis believes that there are two aspects
.
On the one hand, the company is mainly committed to the research and development of traditional Chinese medicine secret recipes, prescriptions and Western medicine preparations, the production of ancient Han health essence (oral liquid, tablets), Yangxin palpitation granules, kidney strengthening pills and other proprietary Chinese medicines, as well as large-volume injections, APIs, five-dimensional lysine oral solution and other Western medicine preparations
.
On the other hand, the company has established provincial enterprise technology center, Hunan traditional Chinese medicine liquid preparation engineering technology center and other research and development platforms, through independent research and development and cooperative development and other ways to continuously cultivate and improve the company's technological innovation ability and scientific research level
.
Conclusion Overall, the Chinese medicine sector of the subdivision sector performed well, and the news was mainly affected
by favorable policies.
On October 27, the "14th Five-Year Plan for the Development of Chinese Medicine Talents" was released, proposing that by 2025, the system and mechanism for the development of Chinese medicine talents in line with the characteristics of Chinese medicine will be more perfect, the training and evaluation system will be more reasonable, the scale of talents will grow rapidly, the structural layout will be more reasonable, the growth environment will be significantly optimized, and a team of high-quality Chinese medicine talents will be cultivated and early to provide stronger talent support
for the revitalization and development of Chinese medicine.
The industry believes that in recent years, a series of supporting policies to support the Chinese medicine industry from the research and development end to the market end and the hospital end have been introduced one after another, and the market space of the Chinese medicine industry is broad
in the future.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice
to anyone.